Top

Published in:

01-11-2008 | Research Paper

Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: a retrospective study of 61 cases

Authors: Yan Gu, Xiaoliang Qi, Shanyu Guo

Published in: Clinical & Experimental Metastasis | Issue 7/2008

Abstract

Purpose To evaluate lymphangiogenesis in patients with breast carcinoma, explore the underlying mechanism, and study the relationship between lymphangiogenesis and progression of breast carcinoma. Methods Sixty-one cases of breast carcinoma with complete clinical and pathological data were analyzed. Using an anti-podoplanin monoclonal antibody, an immunohistochemical study was made of all specimens to detect lymphatic vessel density (LVD) and to investigate its clinicopathological and prognostic value. VEGF-C and VEGF-D were observed by RT-PCR and immunostaining to investigate their clinicopathological and prognostic values and their relationship with lymphangiogenesis. Results LVD in breast carcinoma (6.28 ± 3.73) was significantly higher than in benign mammary lesions (0.50 ± 1.27), P < 0.01 and was significantly associated with lymphatic metastasis and high TNM stage, P < 0.01. The level of VEGF-C and VEGF-D expression was also significantly higher in breast carcinomas than in benign mammary lesions, P < 0.01. LVD increased significantly with higher expression of VEGF-C and VEGF-D, P < 0.01. Patients with high expression of VEGF-C and VEGF-D were observed to be more likely to have a bad outcome, P < 0.05. Conclusions Lymphangiogenesis was significantly associated with lymph node metastasis, high TNM, and poor outcome in breast carcinoma. LVD may serve as a predictor of lymph node metastasis and a prognostic factor in breast carcinoma. VEGF-C and VEGF-D play an important role in lymphangiogenesis making the carcinoma more aggressive and leading to a poor prognosis.

Stewart B, Kleihues P (2003) International agency on research for cancer. In: World Health Organization. World Cancer Report. IARC Press, Lyon, pp 188–190

Cowin P, Welch DR (2007) Breast cancer progression: controversies and consensus in the molecular mechanisms of metastasis and EMT. J Mammary Gland Biol Neoplasia 12:99–102. doi:10.1007/s10911-007-9041-9 PubMedCrossRef

Zheng Y, Li DL, Xiang YM et al (2001) The status and trend of breast cancer incidence in Shanghai. J Surg Concepts Pract 6:219–221

Ji RC (2006) Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: new insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev 25:677–694. doi:10.1007/s10555-006-9026-y PubMedCrossRef

Swartz MA, Skobe M (2001) Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech 55:92–99. doi:10.1002/jemt.1160 PubMedCrossRef

Breiteneder-Geleff S, Matsui K, Soleiman A et al (1997) Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 151:1141–1152PubMed

Birner P, Schindl M, Obermair A et al (2001) Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer. Int J Cancer 95:29–33. doi:10.1002/1097-0215(20010120)95:1≤29::AID-IJC1005≥3.0.CO;2-WPubMedCrossRef

Kurahara H, Takao S, Maemura K et al (2004) Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin Cancer Res 10:8413–8420. doi:10.1158/1078-0432.CCR-04-0379 PubMedCrossRef

Pepper MS (2000) Lymphangiogenesis and tumor metastasis more questions than answers. Lymphology 33:144–147PubMed

10.

Pepper MS (2001) Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 7:462–468PubMed

11.

Schoppmann SF, Birner P, Studer P et al (2001) Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer. Anticancer Res 21:2351–2355PubMed

12.

Kato S, Shimoda H, Ji RC et al (2006) Lymphangiogenesis and expression of specific molecules as lymphatic endothelial cell markers. Anat Sci Int 81:71–83. doi:10.1111/j.1447-073X.2006.00142.x PubMedCrossRef

13.

Breiteneder-Geleff S, Soleiman A, Kowalski H et al (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154:385–394PubMed

14.

Birner P, Schindl M, Obermair A et al (2000) Lymphatic microvessel density in epithelial ovarian cancer: its impact on prognosis. Anticancer Res 20:2981–2985PubMed

15.

16.

Yuan P, Temam S, El-Naggar A et al (2006) Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 107:563–569. doi:10.1002/cncr.22061 PubMedCrossRef

17.

Kato Y, Kaneko MK, Kunita A et al (2008) Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 99:54–61PubMed

18.

Martín-Villar E, Megías D, Castel S et al (2006) Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 119:4541–4553. doi:10.1242/jcs.03218 PubMedCrossRef

19.

Wicki A, Lehembre F, Wick N et al (2006) Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9:261–272. doi:10.1016/j.ccr.2006.03.010 PubMedCrossRef

20.

Renyi-Vamos F, Tovari J, Fillinger J et al (2005) Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 11:7344–7353. doi:10.1158/1078-0432.CCR-05-1077 PubMedCrossRef

21.

Matsumoto K, Nakayama Y, Inoue Y et al (2007) Lymphatic microvessel density is an independent prognostic factor in colorectal cancer. Dis Colon Rectum 50:308–314. doi:10.1007/s10350-006-0792-y PubMedCrossRef

22.

Sedivy R, Beck-Mannagetta J, Haverkampf C et al (2003) Expression of vascular endothelial growth factor-C correlates with the lymphatic microvessel density and the nodal status in oral squamous cell cancer. J Oral Pathol Med 32:455–460. doi:10.1034/j.1600-0714.2003.00168.x PubMedCrossRef

23.

Zeng Y, Opeskin K, Horvath LG et al (2005) Lymphatic vessel density and lymph node metastasis in prostate cancer. Prostate 65:222–230. doi:10.1002/pros.20288 PubMedCrossRef

24.

Kimura N, Kimura I (2005) Podoplanin as a marker for mesothelioma. Pathol Int 55:83–86. doi:10.1111/j.1440-1827.2005.01791.x PubMedCrossRef

25.

Wissmann C, Detmar M (2006) Pathways targeting tumor lymphangiogenesis. Clin Cancer Res 12:6865–6868. doi:10.1158/1078-0432.CCR-06-1800 PubMedCrossRef

26.

Skobe M, Hawighorst T, Jackson DG et al (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7:192–198. doi:10.1038/84643 PubMedCrossRef

27.

Mandriota SJ, Jussila L, Jeltsch M et al (2001) Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumor metastasis. EMBO J 20:672–682. doi:10.1093/emboj/20.4.672 PubMedCrossRef

28.

Nakazato T, Shingaki S, Kitamura N et al (2006) Expression level of vascular endothelial growth factor-C and -A in cultured human oral squamous cell carcinoma correlates respectively with lymphatic metastasis and angiogenesis when transplanted into nude mouse oral cavity. Oncol Rep 15:825–830PubMed

29.

Schietroma C, Cianfarani F, Lacal PM et al (2003) Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer 98:789–797. doi:10.1002/cncr.11583 PubMedCrossRef

30.

Stacker SA, Caesar C, Baldwin ME et al (2001) VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7:186–191. doi:10.1038/84635 PubMedCrossRef

31.

Mohammed RAA, Green A, El-Shikh S et al (2007) Prognostic significance of vascular endothelial cell growth factors-A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 96:1092–1100. doi:10.1038/sj.bjc.6603678 PubMedCrossRef

32.

Mylona E, Alexandrou P, Mpakali A et al (2007) Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma. Eur J Surg Oncol 33:294–300. doi:10.1016/j.ejso.2006.10.015 PubMedCrossRef

33.

Yonemura Y, Fushida S, Bando E et al (2001) Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur J Cancer 37:918–923. doi:10.1016/S0959-8049(01)00015-6 PubMedCrossRef

34.

Al-Rawi MA, Mansel RE, Jiang WG (2005) Molecular and cellular mechanisms of lymphangiogenesis. Eur J Surg Oncol 31:117–121. doi:10.1016/j.ejso.2004.08.015 PubMedCrossRef

35.

Li YS, Kaneko M, Amatya VJ et al (2006) Expression of vascular endothelial growth factor-C and its receptor in invasive micropapillary carcinoma of the breast. Pathol Int 56:256–261. doi:10.1111/j.1440-1827.2006.01961.x PubMedCrossRef

36.

Swartz MA, Skobe M (2001) Lymphatic function, lymphangiogenesis, and cancer metastasis. Microsc Res Tech 55:92–99. doi:10.1002/jemt.1160 PubMedCrossRef

37.

Von Marschall Z, Scholz A, Stacker SA et al (2005) Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. Int J Oncol 27:669–679

38.

Yonemura Y, Endo Y, Tabata K et al (2005) Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer. Int J Clin Oncol 10:318–327. doi:10.1007/s10147-005-0508-7 PubMedCrossRef

39.

Yasuoka H, Nakamura Y, Zuo H et al (2005) VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 18:1127–1133. doi:10.1038/modpathol.3800402 PubMedCrossRef

40.

Juttner S, Wissmann C, Jons T et al (2006) Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 24:228–240. doi:10.1200/JCO.2004.00.3467 PubMedCrossRef

41.

Onogawa S, Kitadai Y, Amioka T et al (2005) Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in early gastric carcinoma: correlation with clinicopathological parameters. Cancer Lett 226:85–90. doi:10.1016/j.canlet.2004.12.030 PubMedCrossRef

Title: Lymphangiogenesis induced by VEGF-C and VEGF-D promotes metastasis and a poor outcome in breast carcinoma: a retrospective study of 61 cases
Authors: Yan Gu
Xiaoliang Qi
Shanyu Guo
Publication date: 01-11-2008
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 7/2008
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-008-9180-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2008

Tissue microarray analysis reveals strong clinical evidence for a close association between loss of annexin A1 expression and nodal metastasis in gastric cancer

Metastatic breast cancer cells colonize and degrade three-dimensional osteoblastic tissue in vitro

Differential expression of angiogenic factors in peripheral nerve sheath tumors

CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12

Sinusoidal tumor angiogenesis is a key component in hepatocellular carcinoma metastasis

Recruitment of dendritic cells in human liver with metastases

Keynote webinar | Spotlight on antibody–drug conjugates in cancer